Employers & Industry
Caribou Biosciences plans a substantial workforce reduction as it stops development of its two allogeneic CAR-T therapy programs and begins a review of strategic alternatives.
The Berkeley, California, CRISPR genome-editing company said Oct. 6 that it will discontinue further development of vispa-cel and CB-011 and cut costs while its board evaluates options that could include a merger, acquisition, business combination or other transaction. According to a regulatory filing, the board approved the restructuring on Oct. 2. The company has not set a timeline for the review.
Caribou did not disclose how many employees will lose their jobs. The company said the cuts will happen in phases and are expected to be mostly complete in the fourth quarter of 2026, with a limited number of employees staying on through the strategic-review process to support any transaction and wind-down work.
Caribou estimated total restructuring expenses of about $15 million to $19 million. That includes roughly $10 million to $11 million for one-time severance payments, continued healthcare coverage and related costs, plus $5 million to $8 million to wind down two early-stage clinical trials.
Caribou tied the decision to the financing environment for allogeneic CAR-T therapies, which it said has made it increasingly difficult to raise the capital needed to keep advancing the programs.
As of June 30, Caribou reported $113.8 million in cash, cash equivalents and marketable securities.
For biotech workers, the announcement is another example of how financing conditions can turn directly into employment risk even when a scientific program has advanced. The company said vispa-cel was ready for a pivotal trial, with FDA alignment already reached on a phase 3 study design, but financing constraints still drove the decision to stop development and shrink the organization.
Sources
- Caribou Biosciences, Inc., Form 8-K (Items 2.05, 5.02, 7.01 and 8.01), filed October 6, 2026. https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175d8k.htm
- Caribou Biosciences press release, Exhibit 99.1 to Form 8-K, October 6, 2026. https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175dex991.htm
Featured photo: A researcher pipettes a DNA sample at the National Human Genome Research Institute. Representative image of laboratory work; not a Caribou Biosciences facility. Photo: Maggie Bartlett, NHGRI, via Wikimedia Commons (Public domain). Cropped from the original.
